Tag:
Cambridge Biotechnology
Latest Headlines
Latest Headlines
Proximagen strikes deal to buy Cambridge Biotechnology
Armed with an $82 million buyout fund, the UK's Proximagen says it has inked a deal to buy Cambridge Biotechnology from Sweden's Biovitrum. Proximagen--which raised 50 million pounds in a fundraising
Biovitrum to spin out small molecule subsidiary
Sweden's Biovitrum announced that it will spin out its small molecule subsidiary Cambridge Biotechnology (CBT). CBT's pipeline includes one Phase II neuropathic pain project; Phase II and Phase I
